 Erin Schenk
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 29 | 2026 | 2637 | 3.530 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 21 | 2026 | 1180 | 3.240 |
Why?
| | Platinum | 1 | 2019 | 50 | 0.600 |
Why?
| | ErbB Receptors | 6 | 2024 | 627 | 0.560 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1953 | 0.540 |
Why?
| | Tumor Microenvironment | 6 | 2022 | 732 | 0.500 |
Why?
| | Neoplasm Staging | 6 | 2026 | 1462 | 0.470 |
Why?
| | Mutation | 6 | 2024 | 4089 | 0.470 |
Why?
| | Biomarkers, Tumor | 9 | 2026 | 1313 | 0.450 |
Why?
| | B7-H1 Antigen | 3 | 2026 | 241 | 0.450 |
Why?
| | Sarcoma | 1 | 2017 | 205 | 0.430 |
Why?
| | Protein Kinase Inhibitors | 5 | 2026 | 969 | 0.430 |
Why?
| | Acrylamides | 2 | 2024 | 70 | 0.420 |
Why?
| | Aniline Compounds | 2 | 2024 | 119 | 0.400 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 253 | 0.390 |
Why?
| | Cytarabine | 1 | 2012 | 66 | 0.370 |
Why?
| | Neoplasms | 4 | 2026 | 2875 | 0.320 |
Why?
| | Protein Kinases | 1 | 2012 | 315 | 0.320 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 462 | 0.280 |
Why?
| | Immunotherapy | 4 | 2020 | 653 | 0.280 |
Why?
| | Pyrimidines | 4 | 2024 | 532 | 0.280 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 628 | 0.280 |
Why?
| | Humans | 38 | 2026 | 144759 | 0.260 |
Why?
| | CD3 Complex | 1 | 2026 | 111 | 0.240 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2194 | 0.230 |
Why?
| | Survival Rate | 5 | 2026 | 2089 | 0.230 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 682 | 0.230 |
Why?
| | Pemetrexed | 1 | 2024 | 38 | 0.220 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2024 | 4 | 0.220 |
Why?
| | Antigens, Neoplasm | 1 | 2026 | 271 | 0.210 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3540 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2024 | 75 | 0.200 |
Why?
| | Oncogenes | 1 | 2024 | 119 | 0.200 |
Why?
| | Neoplasm Proteins | 1 | 2026 | 442 | 0.190 |
Why?
| | Oncogene Addiction | 1 | 2023 | 6 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2026 | 1560 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2026 | 668 | 0.190 |
Why?
| | Bevacizumab | 1 | 2023 | 167 | 0.180 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8265 | 0.180 |
Why?
| | Receptors, Purinergic P1 | 1 | 2021 | 30 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2024 | 549 | 0.170 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2024 | 291 | 0.160 |
Why?
| | Carbon Monoxide | 1 | 2020 | 82 | 0.160 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 229 | 0.160 |
Why?
| | Benzimidazoles | 1 | 2021 | 190 | 0.160 |
Why?
| | Etoposide | 2 | 2019 | 166 | 0.160 |
Why?
| | Aged | 10 | 2026 | 25913 | 0.150 |
Why?
| | Quinazolines | 1 | 2021 | 266 | 0.150 |
Why?
| | Organophosphorus Compounds | 1 | 2020 | 85 | 0.150 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.150 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 433 | 0.150 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 623 | 0.150 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 338 | 0.150 |
Why?
| | Adenosine | 1 | 2021 | 255 | 0.150 |
Why?
| | Carboplatin | 1 | 2019 | 160 | 0.150 |
Why?
| | Nuclear Proteins | 2 | 2024 | 748 | 0.150 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 364 | 0.140 |
Why?
| | Cisplatin | 2 | 2019 | 334 | 0.140 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 212 | 0.140 |
Why?
| | Middle Aged | 11 | 2026 | 35875 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1455 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2019 | 169 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 405 | 0.130 |
Why?
| | Lymphocyte Count | 1 | 2017 | 164 | 0.130 |
Why?
| | Male | 13 | 2026 | 72315 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 199 | 0.120 |
Why?
| | Antigens, CD19 | 1 | 2017 | 129 | 0.120 |
Why?
| | Complement Activation | 1 | 2019 | 411 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 919 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 784 | 0.120 |
Why?
| | Female | 12 | 2026 | 78271 | 0.110 |
Why?
| | Indoles | 3 | 2024 | 501 | 0.110 |
Why?
| | ROC Curve | 1 | 2017 | 614 | 0.110 |
Why?
| | Genomics | 1 | 2020 | 834 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2020 | 529 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 917 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2019 | 2029 | 0.110 |
Why?
| | Monocytes | 1 | 2017 | 538 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 881 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 2027 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2023 | 1318 | 0.100 |
Why?
| | Bortezomib | 1 | 2013 | 55 | 0.100 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.100 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1716 | 0.100 |
Why?
| | Lactams, Macrocyclic | 1 | 2013 | 51 | 0.090 |
Why?
| | Benzoquinones | 1 | 2013 | 47 | 0.090 |
Why?
| | Checkpoint Kinase 1 | 1 | 2012 | 27 | 0.090 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 69 | 0.090 |
Why?
| | Pyrazines | 1 | 2013 | 92 | 0.090 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 99 | 0.090 |
Why?
| | Mass Screening | 1 | 2020 | 1347 | 0.090 |
Why?
| | Molecular Chaperones | 3 | 2002 | 200 | 0.090 |
Why?
| | B7-1 Antigen | 2 | 2008 | 55 | 0.090 |
Why?
| | Medical Oncology | 2 | 2024 | 332 | 0.080 |
Why?
| | Prognosis | 3 | 2026 | 4282 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2026 | 11679 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 509 | 0.070 |
Why?
| | Adult | 7 | 2026 | 40449 | 0.070 |
Why?
| | Mice | 7 | 2026 | 18339 | 0.070 |
Why?
| | Prospective Studies | 1 | 2020 | 7990 | 0.070 |
Why?
| | Interleukin-17 | 1 | 2008 | 118 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 202 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2020 | 264 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1720 | 0.060 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 177 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 173 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 401 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 432 | 0.060 |
Why?
| | Immunoglobulin M | 1 | 2007 | 284 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 389 | 0.060 |
Why?
| | Gene Rearrangement | 1 | 2026 | 155 | 0.060 |
Why?
| | Antiporters | 2 | 2002 | 22 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2022 | 1173 | 0.060 |
Why?
| | T-Lymphocyte Subsets | 1 | 2007 | 415 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2012 | 2496 | 0.050 |
Why?
| | Immunoglobulins | 2 | 2002 | 160 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2024 | 17066 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2430 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2024 | 183 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2002 | 202 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1126 | 0.050 |
Why?
| | Animals | 7 | 2026 | 38058 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2024 | 229 | 0.050 |
Why?
| | Autoimmunity | 1 | 2008 | 926 | 0.050 |
Why?
| | HLA-A Antigens | 1 | 2002 | 52 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 2002 | 56 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 688 | 0.040 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2021 | 80 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 128 | 0.040 |
Why?
| | Cell Line | 3 | 2020 | 2882 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 521 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 281 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1257 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 779 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 38 | 0.040 |
Why?
| | Gene Amplification | 1 | 2019 | 120 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2002 | 612 | 0.040 |
Why?
| | Complement C5a | 1 | 2019 | 54 | 0.040 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2024 | 2182 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4557 | 0.040 |
Why?
| | Histones | 1 | 2024 | 669 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 205 | 0.030 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 2 | 2008 | 14 | 0.030 |
Why?
| | Complement Inactivating Agents | 1 | 2019 | 74 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 442 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1496 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 358 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2847 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 1997 | 173 | 0.030 |
Why?
| | Interferon Type I | 1 | 1997 | 145 | 0.030 |
Why?
| | Ecosystem | 1 | 2020 | 589 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 641 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 985 | 0.020 |
Why?
| | Macrophages | 1 | 2020 | 1511 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1982 | 0.020 |
Why?
| | Membrane Transport Proteins | 2 | 2002 | 154 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3863 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5408 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 5992 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2008 | 45 | 0.020 |
Why?
| | Perforin | 1 | 2007 | 21 | 0.020 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2007 | 15 | 0.020 |
Why?
| | Cell Communication | 1 | 2008 | 324 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2008 | 379 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 2008 | 291 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 499 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2007 | 496 | 0.010 |
Why?
| | Vaccines | 1 | 2008 | 389 | 0.010 |
Why?
| | HLA-B15 Antigen | 1 | 2002 | 11 | 0.010 |
Why?
| | Histidine | 1 | 2002 | 66 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2002 | 88 | 0.010 |
Why?
| | Glutamine | 1 | 2002 | 109 | 0.010 |
Why?
| | Substrate Specificity | 1 | 2002 | 388 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 1129 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 205 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 570 | 0.010 |
Why?
| | Cytokines | 1 | 2008 | 2061 | 0.010 |
Why?
| | Ligands | 1 | 2002 | 673 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 940 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1187 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2832 | 0.010 |
Why?
| | Protein Conformation | 1 | 2002 | 946 | 0.010 |
Why?
| | Amino Acids | 1 | 2002 | 521 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1618 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1997 | 266 | 0.010 |
Why?
| | Vincristine | 1 | 1997 | 140 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2002 | 876 | 0.010 |
Why?
| | Peptides | 1 | 2002 | 995 | 0.010 |
Why?
| | Remission Induction | 1 | 1997 | 307 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 2273 | 0.010 |
Why?
| | Doxorubicin | 1 | 1997 | 397 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1370 | 0.010 |
Why?
|
|
Schenk's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|